The biggest black hole ever seen? Scientists find one with mass of 36 billion suns
About 5 billion light-years away from where you're sitting, in one of the most massive galaxies on record, there exists an astonishing black hole. It was only just measured by scientists who managed to peer through the fabric of warped space-time — and it appears to hold a mass equivalent to that of 36 billion suns.
Yes, billion.
"This is amongst the top 10 most massive black holes ever discovered, and quite possibly the most massive," Thomas Collett, study author and a professor at the University of Portsmouth in England, said in a statement.
More specifically, the black hole is found in one of two galaxies that make up the Cosmic Horseshoe system and is what's known as a "dormant" black hole. This means it's a relatively quiet black hole; it isn't actively chomping on matter in its surroundings, as opposed to an active black hole that is accreting matter from a disk that circles it, known as an accretion disk. The black hole at the center of our Milky Way galaxy, Sagittarius A*, is also a dormant black hole — but, for context, it only holds the mass of about 4.15 million suns.
The fact that the Cosmic Horseshoe black hole is found in such a massive galaxy and that Sagittarius A* is found in our more modestly sized Milky Way is probably not a coincidence. In fact, the team behind the new measurement is hoping to learn more about the apparent size connection between supermassive black holes and their parent galaxies.
"We think the size of both is intimately linked," Collett said, "because when galaxies grow they can funnel matter down onto the central black hole. Some of this matter grows the black hole, but lots of it shines away in an incredibly bright source called a quasar. These quasars dump huge amounts of energy into their host galaxies, which stops gas clouds condensing into new stars."
This brings us to another key aspect of the team's findings: the way this black hole was measured to begin with.
The research team was able to utilize a unique approach that doesn't rely on the black hole being an actively accreting one. Without active feeding, black holes can kind of hide behind the veil of the cosmos. It is the accretion itself that usually gives these objects away. Such commotion produces lots of emissions, like X-rays, that scientists here on Earth can detect. Naturally, it's also far easier to measure the precise masses of black holes via such emissions.
However, there is one characteristic of black holes that even dormant ones can't suppress: their immense gravitational pull. And the greater the gravitational pull, the greater the warp in space-time, as predicted by Albert Einstein's general relativity theory.
Where Einstein comes in
In a nutshell, Albert Einstein's famous theory of general relativity explains the true nature of gravity. It suggests that gravity isn't quite an intrinsic, elusive property of an object that pulls things down. In other words, Earth itself isn't really pulling us down to the ground. Rather, general relativity states that objects with mass (all objects, including you and me) warp the four-dimensional fabric of space-time — and these warps influence the motion of other objects caught up in the folds.
For instance, imagine a trampoline on which you place a ball. That ball would warp the trampoline inward. Now, imagine placing a smaller ball on the trampoline. That smaller ball would fall inward as well, along the warped trampoline's fabric and sit right next to the original ball. The trampoline in this case is space-time, the original ball is Earth and the smaller ball is you.
The big caveat in this analogy, however, is that this trampoline exists in three dimensions. We'd need to scale this up to the four-dimensional universe for it to start representing reality more accurately, but our brains have a hard time comprehending that dimension visually.
Importantly for the team's new measurements, something that arises from warped space-time (in the fourth dimension, remember) is that physical matter isn't the only thing affected by the warps. Light gets affected, too — and that includes light emanating from galaxies, such as the other galaxy in the Cosmic Horseshoe. This is the effect the study team managed to take advantage of when spotting the newly confirmed black hole. Light from the Cosmic Horseshoe system's background galaxy was warped as it traveled past the foreground galaxy that contains black hole.
The Cosmic Horseshoe system is actually an iconic example of this effect, which is called gravitational lensing. Not only does this system have a strong version of this effect, but each galaxy involved happens to be perfectly aligned such that the light-warped background galaxy appears as almost a perfect ring around the foreground galaxy. When this happens, it's called an "Einstein Ring." So, we're seeing an "almost" Einstein ring in this case. It's more like ... an Einstein horseshoe?
After combining those gravitational lensing measurements with measurements of stars in the vicinity that appeared to be zipping around at high speeds, the researchers knew they were onto something. Though scientists have previously suggested a monster black hole lurks in the Cosmic Horseshoe system, concrete evidence of the object and of its precise size wasn't available until now.
"We detected the effect of the black hole in two ways — it is altering the path that light takes as it travels past the black hole and it is causing the stars in the inner regions of its host galaxy to move extremely quickly (almost 400 km/s)," Collet said. "By combining these two measurements, we can be completely confident that the black hole is real."
"Its detection relied purely on its immense gravitational pull and the effect it has on its surroundings," Carlos Melo, study lead author and a Ph.D. candidate at the Universidade Federal do Rio Grande do Sul in Brazil, said in the statement. "What is particularly exciting is that this method allows us to detect and measure the mass of these hidden ultramassive black holes across the universe, even when they are completely silent."
What's next?
There are quite a few ways to move forward on this work, one of which is, as mentioned, to reveal the link between galaxy size and supermassive black hole size — but another could be to zero in on the Cosmic Horseshoe black hole alone and learn how it became so utterly gigantic.
The Cosmic Horseshoe is what's known as a "fossil group," which refers to the end stage of the "most massive gravitationally bound structures in the universe, arising when they have collapsed down to a single extremely massive galaxy, with no bright companions," according to the statement.
The Milky Way and Andromeda galaxies will likely become a fossil group someday, seeing as they're likely on a path to colliding somewhere in the far future. That crash has recently been brought into question, but it's still a possibility. Nonetheless, the Cosmic Horseshoe could very well be a peek into our realm's final era.
"It is likely that all of the supermassive black holes that were originally in the companion galaxies have also now merged to form the ultramassive black hole that we have detected," said Collett. "So we're seeing the end state of galaxy formation and the end state of black hole formation."
The team's paper was published on Aug. 7 in the journal Monthly Notices of the Royal Astronomical Society.
Solve the daily Crossword
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Washington Post
an hour ago
- Washington Post
Trump executive order gives politicians control over all federal grants, alarming researchers
NEW YORK — An executive order signed by President Donald Trump late Thursday aims to give political appointees power over the billions of dollars in grants awarded by federal agencies . Scientists say it threatens to undermine the process that has helped make the U.S. the world leader in research and development.
Yahoo
2 hours ago
- Yahoo
Eating too many French fries could increase risk of Type 2 diabetes: Study
Apparently, there is such a thing as too many French fries. And it's also not just about the amount of fries you could be eating in one sitting but also how many times a week you consume the tasty taters a week that could increase an individual's risk of developing Type 2 diabetes. According to a study published in the British Medical Journal, eating three or more servings of fries each week can increase the chance of developing the chronic condition by 20%, while eating fries five times a week can increase the chance by 27%. 'Our findings underscore that the association between potato intake and type 2 diabetes risk depends on the specific foods used as replacement,' the researchers said. 'The findings also align with current dietary recommendations that promote the inclusion of whole grains as part of a healthy diet for the prevention of type 2 diabetes.' The researchers did note that eating similar amounts of potatoes cooked other ways — boiled, baked or mashed, for example — does not substantially increase the risk, only reducing it by 5%. 'The high starch content of potatoes, leading to a high glycemic index and load, combined with possible loss of nutrients and possible health risks resulting from various cooking methods, could contribute to adverse health outcomes,' the study explains. More than 22,000 cases of Type 2 diabetes were documented during the 37-year time period. RECOMMENDED VIDEO 'Potatoes can be part of a healthy diet, but it's how we prepare them that makes the difference,' Dr. Kawther Hashem, a lecturer in public health nutrition at Queen Mary University of London and not involved with the study, told the Guardian. 'Boiled, baked or mashed potatoes are naturally low in fat and a source of fibre, vitamin C and potassium,' Hashem continued. 'But when we deep fry them into French fries, especially in large portions and with added salt, they become less healthy with their high-fat, salt and calorie content that's much more likely to contribute to weight gain and increase the risk of type 2 diabetes.' For the study, an international team of researchers examined the diets of more than 205,000 adults in the United States who had their eating habits documented every four years between 1984 and 2021. Sink your teeth into this: Red meat again linked to Type 2 diabetes risk Dark chocolate may lower risk of developing Type 2 diabetes SYRON: Misleading diabetes ads on social media pose a serious health risk 'Not all potatoes are created equal,' lead author Seyed Mohammad Mousavid, a research fellow at the Harvard T.H. Chan School of Public Health, told NBC News. 'Even a small amount of french fries, less than one serving in the week, is associated with a higher risk of Type 2 diabetes.' Replacing potatoes with whole grains, on the other hand, lowers the risk of diabetes by 8%, and if grains are eaten instead of fries specifically, that cuts the risk by 19%. White rice, however, had a stronger association with diabetes.
Yahoo
2 hours ago
- Yahoo
U.S. FDA grants accelerated approval to Boehringer's HERNEXEOS® as first orally administered targeted therapy for previously treated patients with HER2-mutant advanced NSCLC
Illustrative image This press release is not intended for UK media. HERNEXEOS® (zongertinib tablets) approved based on an objective response rate of 75% (N=71), as demonstrated in the Beamion-LUNG 1 clinical trial1 Accelerated approval follows Priority Review and Breakthrough Therapy Designation granted by the U.S. FDA for the treatment of patients with HER2 (ERBB2)-mutant advanced non-small cell lung cancer Ridgefield, Conn. U.S. and Ingelheim, Germany - Boehringer Ingelheim's HERNEXEOS® (zongertinib tablets) has been approved by the U.S. Food and Drug Administration (FDA). The kinase inhibitor is indicated for the treatment of adult patients with unresectable or metastatic non-squamous non-small cell lung cancer (NSCLC) whose tumors have HER2 (ERBB2) tyrosine kinase domain activating mutations, as detected by an FDA-approved test, and who have received prior systemic therapy.1 This indication is approved under accelerated approval based on objective response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.1 'With the approval of zongertinib, we have an effective, targeted, orally administered treatment option for patients with HER2 (ERBB2)-mutant non-small cell lung cancer in the U.S. that not only elicits a durable response but, importantly, has a manageable safety profile,' said Dr. John Heymach, MD, PhD, chair of Thoracic/Head and Neck Medical Oncology at The University of Texas MD Anderson Cancer Center, and coordinating investigator for the Beamion-LUNG 1 trial. 'In a patient population where there are currently limited treatment options, this approval represents a significant advancement in cancer care.' Accelerated approval is based on data from the Phase Ib Beamion-LUNG 1 trial, demonstrating an objective response rate of 75% (N=71), 6% of patients had a complete response and 69% of patients had a partial response and a duration of response of ≥6 months in 58% of patients (n=53).1 Positive results from the Beamion-LUNG 1 trial were previously presented at the American Association for Cancer Research (AACR) Annual Meeting 2025 and simultaneously published in The New England Journal of Medicine.2 Zongertinib demonstrated a manageable safety profile with a 2.9% discontinuation rate. In the pooled safety population, the most common (> 20%) adverse reactions were diarrhea (53%), hepatotoxicity (27%), rash (27%), fatigue (22%), and nausea (21%).1 'We are grateful to be able to bring forward HERNEXEOS, which has the potential to reset the benchmark for those living with HER2-mutant advanced non-small cell lung cancer, a condition associated with a particularly poor prognosis,' said Shashank Deshpande, Chairman of the Board of Managing Directors and Head of Human Pharma at Boehringer Ingelheim. 'Believing in the power of scientific innovation, we aim to provide meaningful improvements to this patient population. Recognizing its potential, we accelerated development to deliver this new treatment option to patients within four years of starting the first clinical trial." Harnessing the power of precision medicine by targeting HER2 mutations in lung cancer HER2 (ERBB2) mutations occur in approximately 2–4% of NSCLC cases and are associated with a poor prognosis and higher incidence of brain metastases.3,4,5 Alterations in the HER2 (ERBB2) gene, including mutations, amplification and overexpression, trigger uncontrolled cell proliferation, inhibiting cell death, and promoting tumor growth and spread.3,5 Comprehensive biomarker testing using next generation sequencing determines a patient's eligibility for treatment with zongertinib by identifying HER2 (ERBB2)-mutant advanced NSCLC.1,5 'The advocacy community is thrilled about the approval of zongertinib, as it is another testament to the importance of personalized options for lung cancer that allow for a much more targeted approach for a subgroup of patients who have been waiting many years for innovative treatments,' said Marcia Horn, President and CEO, International Cancer Advocacy Network and Executive Director of the Exon 20 Group/HER2 Warriors. 'Understanding your cancer's unique biomarkers, including HER2, through comprehensive testing is critical for all patients with NSCLC, as it can unlock targeted treatment options.' About non-small cell lung cancer (NSCLC) Lung cancer claims more lives than any other cancer type and the incidence is set to increase to over 3 million cases worldwide by 2040.5,6 NSCLC is the most common type of lung cancer.3 Due to a lack of symptoms and misdiagnoses,7 most patients with NSCLC present at stage III or IV, where the disease has metastasized locally or to other organs.8 The estimated 5-year survival rate historically has been less than 10% for metastatic disease.9,10,11 People living with advanced NSCLC can experience a detrimental physical, psychological, and emotional impact on their daily lives.12,13,14 About zongertinib Zongertinib is a tyrosine kinase inhibitor (TKI) that selectively inhibits HER2 (ERBB2).1 This orally administered, targeted therapy was approved as HERNEXEOS® (zongertinib tablets) under the FDA's Accelerated Approval Program, after securing Priority Review as well as Breakthrough Therapy and Fast Track Designations.1 The treatment is being evaluated in ongoing trials, across a range of advanced solid tumors with HER2 alterations. About Boehringer Ingelheim in oncology We have a clear aspiration – to transform the lives of people with cancer by delivering meaningful advances, with the ultimate goal of curing a range of cancers. Boehringer Ingelheim's generational commitment to driving scientific innovation is reflected by the company's robust pipeline of cancer cell-directed and immuno-oncology investigational therapies, as well as the smart combination of these approaches. Boehringer's ambition in oncology is to take a diligent and broad approach, creating a collaborative research network to tap into a diversity of minds, which is vital in addressing some of the most challenging, but potentially most impactful, areas of cancer research. Simply put, for Boehringer Ingelheim, cancer care is personal, today and for generations. Read more at and, About Boehringer Ingelheim Boehringer Ingelheim is a biopharmaceutical company active in both human and animal health. As one of the industry's top investors in research and development, the company focuses on developing innovative therapies that can improve and extend lives in areas of high unmet medical need. Independent since its foundation in 1885, Boehringer takes a long-term perspective, embedding sustainability along the entire value chain. Our approximately 54,500 employees serve over 130 markets to build a healthier and more sustainable tomorrow. Learn more at and The following information is intended for U.S. audiences only: About HERNEXEOS® HERNEXEOS® (zongertinib tablets) is a kinase inhibitor indicated for the treatment of adult patients with unresectable or metastatic non-squamous non-small cell lung cancer (NSCLC) whose tumors have HER2 (ERBB2) tyrosine kinase domain activating mutations, as detected by an FDA-approved test, and who have received prior systemic therapy. Boehringer Ingelheim's CareConnect4Me patient support program Boehringer's goal is to make HERNEXEOS® (zongertinib tablets) easily accessible in the U.S. through a comprehensive patient support program, CareConnect4MeTM, that provides a broad range of access and clinical support solutions, including financial support services. For those in the U.S., visit or call 1-855-297-5903 to learn more. What is HERNEXEOS (zongertinib tablets)? HERNEXEOS is a prescription medicine used to treat adults with a type of lung cancer called non-squamous non-small cell lung cancer (NSCLC) that: cannot be removed by surgery or that has spread to other parts of your body (metastatic), an has a certain mutation in the human epidermal growth factor receptor 2 (HER2) gene, and who have previously received treatment by mouth or injection (systemic therapy). Your healthcare provider will perform a test to make sure HERNEXEOS is right for you. It is not known if HERNEXEOS is safe and effective in children. IMPORTANT SAFETY INFORMATION Before taking HERNEXEOS, tell your healthcare provider about all of your medical conditions, including if you: have liver problems. have heart problems. have lung or breathing problems other than lung cancer. are pregnant or plan to become pregnant. HERNEXEOS can harm your unborn baby. Females who are able to become pregnant: Your healthcare provider will do a pregnancy test before you start treatment with HERNEXEOS. Use an effective form of birth control (contraception) during treatment with HERNEXEOS and for 2 weeks after your last dose. Talk to your healthcare provider about birth control methods that might be right for you during this time. Tell your healthcare provider right away if you become pregnant or think you are pregnant during treatment with HERNEXEOS. are breastfeeding or plan to breastfeed. It is not known if HERNEXEOS passes into your breastmilk. Do not breastfeed during treatment and for 2 weeks after your last dose of HERNEXEOS. Tell your healthcare provider about all the medicines you take, including prescription and over-the- counter medicines, vitamins, and herbal supplements. HERNEXEOS may affect the way other medicines work, and other medicines may affect how HERNEXEOS works. Know the medicines you take. Keep a list of them to show your healthcare provider or pharmacist when you get a new medicine. What are the possible side effects of HERNEXEOS? HERNEXEOS may cause serious side effects, including: liver problems. Liver problems are common with HERNEXEOS and can be severe and life threatening. Your healthcare provider will do blood tests to check your liver function before you start taking HERNEXEOS and during your treatment. Tell your healthcare provider right away if you develop any signs and symptoms of liver problems, including: yellowing of your skin or the white part of your eyes (jaundice) dark or brown (tea colored) urine pain on the upper right side of your stomach area (abdomen) bleeding or bruising more easily than normal feeling very tired loss of appetite nausea or vomiting heart problems that may affect your heart's ability to pump blood. HERNEXEOS can cause heart problems. Your healthcare provider will do tests to check your heart function before you start taking HERNEXEOS and during treatment. Tell your healthcare provider right away if you have any new or worsening symptoms of heart problems, including: feeling like your heart is pounding or racing Dizziness Tiredness feeling lightheaded shortness of breath loss of consciousness coughing swelling of your legs, ankles, or feet lung problems. HERNEXEOS can cause lung problems that are severe or life-threatening. Tell your healthcare provider right away if you have any new or worsening symptoms of lung problems, including trouble breathing, shortness of breath, cough, or fever. Your healthcare provider may temporarily stop, decrease your dose, or permanently stop treatment with HERNEXEOS if you have serious side effects. The most common side effects of HERNEXEOS include: diarrhea. HERNEXEOS can cause severe diarrhea. Tell your healthcare provider right away if you have diarrhea. liver problems Rash feeling tired nausea The most common severe abnormal blood tests include decreased white blood cell count, increased liver function tests, and decreased potassium levels. HERNEXEOS may cause fertility problems in females and males, which may affect your ability to have children. Talk to your healthcare provider if this is a concern for you. These are not all of the possible side effects of HERNEXEOS. Call your doctor for medical advice about side effects. For more information, ask your healthcare provider or pharmacist. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit or call 1-800-FDA-1088. For U.S. Healthcare Professionals, please see full Prescribing Information. CL--100065 07.28.2025 References: 1HERNEXEOS Prescribing Information 2Heymach, J. et al. Zongertinib in previously treated HER2-mutant non-small cell lung cancer. N Engl J Med. 2025;01-13. 3Baraibar I, et al. Novel drugs targeting EGFR and HER2 exon 20 mutations in metastatic NSCLC. Crit Rev Oncol Hematol. 2020;148:102906. 4Li, B.T. et al. Trastuzumab Deruxtecan in HER2-Mutant Non–Small-Cell Lung Cancer. N Engl J Med. 2022;386:241–51 5Zeng J, Ma W, Young RB, Li T. Targeting HER2 genomic alterations in non-small cell lung cancer. J Natl Cancer Cent. 2021 May 3;1(2):58-73. 6International Agency for Research on Cancer – World Health Organization. Rates of trachea, bronchus and lung cancer. Available at: (Accessed: January 2025). 7American Cancer Society. Lung Cancer Early Detection, Diagnosis, and Staging. Available at: (Accessed: January 2025). 8Casal-Mouriño, A. et al. Epidemiology of stage III lung cancer: frequency, diagnostic characteristics, and survival. Transl Lung Cancer Res. 2021;10(1):506-518. 9National Cancer Institute Surveillance, Epidemiology, and End Results (SEER). 5-Year Survival (Accessed July 2025). 10Belaroussi, Y. et al. Survival outcomes of patients with metastatic non-small cell lung cancer receiving chemotherapy or immunotherapy as first-line in a real-life setting. Sci Rep. 2023.13, 9584. 11Simeone, J. C. et al. Treatment patterns and overall survival in metastatic non-small-cell lung cancer in a real-world US setting. Fut. Oncol. Lond. Engl. 2019. 15(30), 3491–3502. 12Valentine, T. R. et al. Illness Perceptions and Psychological and Physical Symptoms in Newly Diagnosed Lung Cancer. Health Psychol. 2022 Jun; 41(6): 379–388. 13Andersen, B. L. et al. Newly diagnosed patients with advanced non-small cell lung cancer: A clinical description of those with moderate to severe depressive symptoms. Lung Cancer. 2020 Jul;145:195-204. 14Presley, C. J. et al. Functional Disability Among Older Versus Younger Adults With Advanced Non–Small-Cell Lung Cancer. JCO Oncol Pract. 2021 May 3;17(6):e848–e858. Attachment Illustrative imageError in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data